News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Gerry Hanna: PET based inhomogenous dose escalation in stage 3 lung cancer
Gerry Hanna/X
Apr 29, 2025, 10:28

Gerry Hanna: PET based inhomogenous dose escalation in stage 3 lung cancer

Gerry Hanna, Marie Curie Chair of Clinical Oncology at Trinity College Dublin, shared an article by Tine Schytte, et al. on X:

“Might PET based inhomogenous dose escalation be an approach to permit dose escalation in stage 3 lung cancer /NSCLC?

With modest toxicity rates and RT dose escation to median of 88.1 Gy to GTV, The phase 3 NARLAL2 trial suggests it may be RadOnc.”

Gerry Hanna: PET based inhomogenous dose escalation in stage 3 lung cancer

Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non–Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial.

Journal: Journal of Clinical Oncology

Authors: Tine Schytte, et al.

Gerry Hanna: PET based inhomogenous dose escalation in stage 3 lung cancer

More posts featuring Gerry Hanna.

cancer clinical oncology fight against cancer Gerry Hanna Global fight against cancer inhomogenous Lung cancer NARLAL2 trial NSCLC OncoDaily Oncology RadOnc Trinity College Dublin
Special Coverage
Science
Apr 29, 2025, 10:28
Gerry Hanna: PET based inhomogenous dose escalation in stage 3 lung cancer
Blog
Apr 29, 2025, 10:18
Patricia LoRusso: Honoring our 50-Year AACR Members at AACR25
Blog
Apr 29, 2025, 10:16
Aaron Goodman: The UCSD BMT fellowship
Science
Apr 29, 2025, 10:07
Bobby Koneru: Low-Dose Radiation Therapy for Benign Musculoskeletal Disorders
Blog
Apr 29, 2025, 09:54
Laura Vater: Increase in rates of depression in the first year of residency
Science
Apr 29, 2025, 09:47
Praveen Kumar Marimuthu: Neoadjuvant dostarlimab for Stage I–III dMMR solid tumors
Blog
Apr 29, 2025, 09:33
Naveen Pemmaraju: Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed AML
Blog
Apr 29, 2025, 09:23
Chris Poulios: The Young Cancer Professionals group of the European Cancer Organisation
Blog
Apr 29, 2025, 09:16
Navneet Majhail: Congratulations to Stephen Strickland for presenting first-in-human results of SENTI-202
Blog
Apr 29, 2025, 09:10
Ahmed Magdy Rabea: An incredible privilege to participate in the 4th SOH Conference
Blog
Apr 29, 2025, 09:02
Isabel Mestres Announces Candidacy for NCD Alliance Board of Directors 2025–2027
Blog
Apr 29, 2025, 08:54
Women and Cancer: Prevention, Information and Hope - Yale Cancer Center